Breaking News: Teva Announces FDA Grants Approval of AZILECT(R) (Rasagiline) for Parkinson's Disease: "Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) today announced that it has received approval from the U.S. Food and Drug Administration (FDA) for once-daily AZILECT(R) (rasagiline tablets) as a treatment for Parkinson's disease both as initial monotherapy in early Parkinson's disease patients and as adjunct therapy to levodopa in moderate-to-advanced stages of the disease. AZILECT(R) will becomeavailable in the U.S. within 8 to 10 weeks.

Israel Makov, President and CEO of Teva commented, 'We are extremely pleased to receive FDA approval for AZILECT(R), the only once-daily product and one of the few treatment options in the U.S. indicated for all stages of Parkinson's disease including as monotherapy in the early stages and as adjunct to levodopa in the more advanced stages. AZILECT(R) fills an important unmet need, offering a new treatment which uniquely combines efficacy, convenient once-dailydosing and good tolerability. The upcoming launch of AZILECT(R)
represents a key milestone in our commitment to develop and bring to
market novel therapies for neurological diseases......'"